866-997-4948(US-Canada Toll Free)

Peritoneal Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 188 Pages


Global Markets Directs, \'Peritoneal Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. 

Peritoneal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Peritoneal Cancer.
  • A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peritoneal Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Peritoneal Cancer 9
Peritoneal Cancer Therapeutics under Development by Companies 11
Peritoneal Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Peritoneal Cancer Therapeutics - Products under Development by Companies 20
Peritoneal Cancer Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Peritoneal Cancer Therapeutics Development 26
Boehringer Ingelheim GmbH 26
Kyowa Hakko Kirin Co., Ltd. 27
Amgen Inc. 28
Sanofi-Aventis 29
AstraZeneca PLC 30
Eli Lilly and Company 31
Oxford BioMedica plc 32
Millennium Pharmaceuticals, Inc. 33
Novartis AG 34
Cell Therapeutics, Inc. 35
Bayer AG 36
EntreMed, Inc. 37
Marshall Edwards, Inc. 38
Oncolytics Biotech Inc. 39
Array BioPharma Inc. 40
Synta Pharmaceuticals Corp. 41
Spectrum Pharmaceuticals, Inc. 42
Fresenius Biotech GmbH 43
CritiTech, Inc. 44
Viral Genetics, Inc. 45
ImmunoVaccine Technologies Inc. 46
Genelux Corporation 47
TRACON Pharmaceuticals, Inc. 48
RECEPTA Biopharma S.A. 49
Kyowa Hakko Kirin Pharma, Inc. 50
Peritoneal Cancer - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 58
trebananib - Drug Profile 58
enzastaurin hydrochloride - Drug Profile 60
sorafenib tosylate - Drug Profile 62
alisertib - Drug Profile 66
paclitaxel poliglumex - Drug Profile 68
selumetinib sulfate - Drug Profile 72
ENMD-2076 - Drug Profile 74
elesclomol - Drug Profile 76
TroVax - Drug Profile 78
ramucirumab - Drug Profile 80
MEK-162 - Drug Profile 84
vatalanib + [docetaxel] - Drug Profile 87
erlotinib hydrochloride + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile 88
bendamustine hydrochloride - Drug Profile 90
idronoxil + [carboplatin] - Drug Profile 91
Docetaxel + Yondelis + Pegfilgrastim - Drug Profile 92
docetaxel + [trabectedin] + pegfilgrastim - Drug Profile 94
Docetaxel + Carboplatin + Pegfilgrastim - Drug Profile 95
ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine + [sargramostim] - Drug Profile 96
trebananib + [doxorubicin liposomal] - Drug Profile 97
Taxotere + Eloxatin + Avastin - Drug Profile 99
TRC-105 - Drug Profile 101
Monoclonal antibody hu3S193 - Anti-LeY - Drug Profile 103
GL-ONC-1 - Drug Profile 104
pemetrexed disodium + [carboplatin] - Drug Profile 106
pemetrexed disodium + [bevacizumab] - Drug Profile 108
erlotinib hydrochloride + [bevacizumab] - Drug Profile 109
paclitaxel - Drug Profile 111
paclitaxel albumin-bound + [bevacizumab] - Drug Profile 113
EGEN-001 - Drug Profile 114
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 116
everolimus + [bevacizumab] - Drug Profile 118
OCDC Dendritic Cell Vaccine - Drug Profile 120
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 121
bevacizumab + [irinotecan hydrochloride] - Drug Profile 122
Reolysin + [paclitaxel] - Drug Profile 123
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile 125
Belotecan + Etoposide - Drug Profile 126
SJG-136 - Drug Profile 127
belinostat + [carboplatin] - Drug Profile 128
Carcinoembryonic antigen-expressing measles virus - Drug Profile 129
Docetaxel + Yondelis + Filgrastim - Drug Profile 130
Docetaxel + Gemcitabine - Drug Profile 132
vandetanib + [docetaxel] - Drug Profile 134
5-Fluorouracil + Isovorin - Drug Profile 135
trebananib + [carboplatin] + [paclitaxel] - Drug Profile 136
KHK-2866 + [carboplatin] + [gemcitabine hydrochloride] - Drug Profile 138
KHK-2866 + [paclitaxel] - Drug Profile 140
KHK-2866 + [doxorubicin] 142
- Drug Profile 142
KHK-2866 - Drug Profile 144
nintedanib + [carboplatin] + [doxorubicin] - Drug Profile 145
ABT-767 - Drug Profile 147
Pb-TCMC-Trastuzumab - Drug Profile 148
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate - Drug Profile 149
pazopanib hydrochloride + [carboplatin] + [paclitaxel] - Drug Profile 150
pazopanib hydrochloride + [paclitaxel] - Drug Profile 152
EGEN-001 + Doxil - Drug Profile 153
catumaxomab - Drug Profile 154
dalantercept - Drug Profile 155
hydroxychloroquine + sorafenib - Drug Profile 156
Pralatrexate + Carboplatin - Drug Profile 157
Peritoneal Cancer Therapeutics - Drug Profile Updates 158
Peritoneal Cancer Therapeutics - Discontinued Products 173
Peritoneal Cancer Therapeutics - Dormant Products 174
Peritoneal Cancer - Product Development Milestones 178
Featured News & Press Releases 178

Appendix 183

Methodology 183
Coverage 183
Secondary Research 183
Primary Research 183
Expert Panel Validation 183
Contact Us 184
Disclaimer 184

List of Table


Number of Products Under Development for Peritoneal Cancer, H1 2013 13
Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 20
Comparative Analysis by Late Stage Development, H1 2013 21
Comparative Analysis by Mid Clinical Stage Development, H1 2013 22
Comparative Analysis by Early Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Development by Companies, H1 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2013 27
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 28
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 29
Boehringer Ingelheim GmbH, H1 2013 30
Kyowa Hakko Kirin Co., Ltd., H1 2013 31
Amgen Inc., H1 2013 32
Sanofi-Aventis, H1 2013 33
AstraZeneca PLC, H1 2013 34
Eli Lilly and Company, H1 2013 35
Oxford BioMedica plc, H1 2013 36
Millennium Pharmaceuticals, Inc., H1 2013 37
Novartis AG, H1 2013 38
Cell Therapeutics, Inc., H1 2013 39
Bayer AG, H1 2013 40
EntreMed, Inc., H1 2013 41
Marshall Edwards, Inc., H1 2013 42
Oncolytics Biotech Inc., H1 2013 43
Array BioPharma Inc., H1 2013 44
Synta Pharmaceuticals Corp., H1 2013 45
Spectrum Pharmaceuticals, Inc., H1 2013 46
Fresenius Biotech GmbH, H1 2013 47
CritiTech, Inc., H1 2013 48
Viral Genetics, Inc., H1 2013 49
ImmunoVaccine Technologies Inc., H1 2013 50
Genelux Corporation, H1 2013 51
TRACON Pharmaceuticals, Inc., H1 2013 52
RECEPTA Biopharma S.A., H1 2013 53
Kyowa Hakko Kirin Pharma, Inc., H1 2013 54
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Stage and Molecule Type, H1 2013 61
Peritoneal Cancer Therapeutics - Drug Profile Updates 162
Peritoneal Cancer Therapeutics - Discontinued Products 177
Peritoneal Cancer Therapeutics - Dormant Products 178
Peritoneal Cancer Therapeutics - Dormant Products (Contd..1) 179
Peritoneal Cancer Therapeutics - Dormant Products (Contd..2) 180
Peritoneal Cancer Therapeutics - Dormant Products (Contd..3) 181

List of Chart


Number of Products under Development for Peritoneal Cancer, H1 2013 13
Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 21
Mid Clinical Stage Products, H1 2013 22
Early Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Route of Administration, H1 2013 57
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Molecule Type, H1 2013 59
Assessment by Stage and Molecule Type, H1 2013 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *